Magnus Berle1,2,3, Kjersti E Hestetun4,5, Heidrun Vethe6, Simona Chera4,7, Joao A Paulo8, Olav Dahl4,5, Mette Pernille Myklebust5. 1. Department of Clinical Medicine, University of Bergen, Bergen, Norway; magnus.berle@uib.no. 2. Department of Surgery, Haukeland University Hospital, Bergen, Norway. 3. Department of Surgery, Haraldsplass Deaconess Hospital, Bergen, Norway. 4. Department of Clinical Science, University of Bergen, Bergen, Norway. 5. Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway. 6. Department of Clinical Medicine, University of Bergen, Bergen, Norway. 7. Department of Medicine, Division of Endocrinology, Diabetes, Nutrition and Patient Education, University Hospital of Geneva, Geneva, Switzerland. 8. Department of Cell Biology, Harvard Medical School, Boston, MA, U.S.A.
Abstract
BACKGROUND/AIM: Better stratification of the risk of relapse will help select the right patients for adjuvant treatment and improve targeted therapies for patients with colon cancer. MATERIALS AND METHODS: To understand why a subset of tumors relapse, we compared the proteome of two groups of patients with colon cancer with similar stage, stratified based on the presence or absence of recurrence. RESULTS: Using tumor biopsies from the primary operation, we identified dissimilarity between recurrent and nonrecurrent mismatch satellite stable colon cancer and found that signaling related to immune activation and inflammation was associated with relapse. CONCLUSION: Immune modulation may have an effect on mismatch satellite stable colon cancer. At present, immune therapy is offered primarily to microsatellite instable colon cancer. Hopefully, immune therapy in mismatch satellite stable colon cancer beyond PD-1 and PD-L1 inhibitors can be implemented.
BACKGROUND/AIM: Better stratification of the risk of relapse will help select the right patients for adjuvant treatment and improve targeted therapies for patients with colon cancer. MATERIALS AND METHODS: To understand why a subset of tumors relapse, we compared the proteome of two groups of patients with colon cancer with similar stage, stratified based on the presence or absence of recurrence. RESULTS: Using tumor biopsies from the primary operation, we identified dissimilarity between recurrent and nonrecurrent mismatch satellite stable colon cancer and found that signaling related to immune activation and inflammation was associated with relapse. CONCLUSION: Immune modulation may have an effect on mismatch satellite stable colon cancer. At present, immune therapy is offered primarily to microsatellite instable colon cancer. Hopefully, immune therapy in mismatch satellite stable colon cancer beyond PD-1 and PD-L1 inhibitors can be implemented.
Authors: J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein Journal: Nature Date: 1987 May 28-Jun 3 Impact factor: 49.962
Authors: Daniele V F Tauriello; Sergio Palomo-Ponce; Diana Stork; Antonio Berenguer-Llergo; Jordi Badia-Ramentol; Mar Iglesias; Marta Sevillano; Sales Ibiza; Adrià Cañellas; Xavier Hernando-Momblona; Daniel Byrom; Joan A Matarin; Alexandre Calon; Elisa I Rivas; Angel R Nebreda; Antoni Riera; Camille Stephan-Otto Attolini; Eduard Batlle Journal: Nature Date: 2018-02-14 Impact factor: 49.962
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Graeme C McAlister; David P Nusinow; Mark P Jedrychowski; Martin Wühr; Edward L Huttlin; Brian K Erickson; Ramin Rad; Wilhelm Haas; Steven P Gygi Journal: Anal Chem Date: 2014-07-03 Impact factor: 8.008